Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
01:38pm, Thursday, 07'th May 2026
Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to news regarding its clinical trial data in Duchenne muscular dystrophy patients.
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
09:56am, Thursday, 07'th May 2026
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $0.42 per share a year ago.
Entrada Therapeutics Reports First Quarter 2026 Financial Results
07:10am, Thursday, 07'th May 2026
500 - Internal server error. Server Error 500 - Internal server error.
Entrada's Duchenne drug shown to improve muscle function in early trial
07:04am, Thursday, 07'th May 2026
Entrada Therapeutics said on Thursday its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease, in an early-to-mid �
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all
Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
10:16am, Tuesday, 05'th May 2026
Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade
01:44am, Tuesday, 07'th Apr 2026
Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday after Oppenheimer raised their price target on the stock from $21.00 to $23.00.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts
04:46am, Saturday, 07'th Mar 2026
Entrada Therapeutics, Inc. (NASDAQ: TRDA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five ratings firms that are covering the company, MarketBeat Ratings repor
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 02'nd Mar 2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hi
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Thursday, 26'th Feb 2026
– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Indep
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
11:01am, Thursday, 19'th Feb 2026
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit
02:03am, Tuesday, 17'th Feb 2026
Entrada Therapeutics (NASDAQ: TRDA) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinica
Entrada Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 04'th Feb 2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biot
